DUBLIN, June  29, 2026  (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical

TRIB

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Trinity Biotech terminates SEPA, signaling financing strategy shift

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>DUBLIN, June  29, 2026  (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Trinity Biotech plc announced it has formally terminated its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global, and will not use the SEPA going forward. The move suggests a shift in financing strategy and could reduce near-term dilution risk, while the company emphasizes cash position and growth from Waveform assets and acquisitions. Investors should monitor liquidity runway and Waveform-related opportunities.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Trinity terminates SEPA with YA II PN LTD; no further use of equity line.</li><li>Financing strategy shift; termination reduces potential dilution risk.</li><li>Notes cash position and growth potential from Waveform assets and acquisitions.</li><li>Global footprint: 75+ countries; expanding Trinovium AI data-center cooling.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Trinity Biotech plc (TRIB)</strong>: Announced SEPA termination; potential impact on liquidity and capital strategy.</li><li><strong>Yorkville Advisors Global / YA II PN LTD (N/A)</strong>: Financing partner; termination removes potential future equity funding.</li><li><strong>Waveform Technologies Inc. (N/A)</strong>: Asset acquisition; wearable biosensors; potential synergy with AI cooling via Trinovium.</li><li><strong>Trinovium (N/A)</strong>: Subsidiary expanding fluid manufacturing and analytical capabilities into AI data center cooling.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The news centers on capital structure and financing strategy changes rather than product/earnings milestones.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>SEPA termination reduces potential share dilution, possibly uplifting sentiment.</li><li>Liquidity plan uncertain; greater emphasis on cash runway and alternative financing.</li><li>Waveform assets and Trinovium cooling initiatives could unlock new revenue streams.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Announcement date: June 29, 2026.</li><li>Terminated Standby Equity Purchase Agreement with YA II PN LTD.</li><li>SEPA will not be used further; reflects a change in financing strategy.</li><li>Company operates in 75+ countries; wearable biosensors; Waveform assets acquired.</li><li>Forward-looking statements reference risks including government HIV funding and currency fluctuations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral-to-bullish near-term; financing flexibility improves but cash runway remains pivotal.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">DUBLIN, June  29, 2026  (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TRIB">TRIB</a>), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the "SEPA") for an equity line of credit facility.</p>  <p align="justify">The Company has determined that it does not intend to make any further use of the SEPA.  Accordingly, termination of the equity line of credit facility reflects the Company’s current financing strategy.</p>  <p align="justify"><strong>Forward-Looking Statements<br></br></strong>This release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to successfully develop and commercialize data center cooling &amp; thermal management solutions for AI and high-performance computing, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the Company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties, and risks related to the condition of the United States economy and other risks detailed under "Risk Factors" in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2025 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</p>  <p align="justify"><strong>About Trinity Biotech</strong><br></br>Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TRIB">TRIB</a>) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc. Through its Trinovium subsidiary, Trinity Biotech is extending its fluid manufacturing and analytical capabilities into advanced liquid cooling solutions for AI data center infrastructure. Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please visit <a href="https://www.globenewswire.com/Tracker?data=hFGqSmUQTbIaoF0CEIC4DHIEnQvCcPlqWb1JYiOnxZE3tvkx-yhnZanAN_4e-Tr9b03Ew0Ed1MqFPiLn149cWDWTNR34D0h-WTQ7DaCClyU=" rel="nofollow" target="_blank">www.trinitybiotech.com</a>.<br></br>.</p> <table align="left" style="border-collapse: collapse; width:1154.81px; border-collapse:collapse ;"><tr><td style="max-width:10%; width:115.469px; min-width:10%;;text-align: left ;  vertical-align: middle; "> </td><td style="max-width:25%; width:288.703px; min-width:25%;;text-align: left ;  vertical-align: middle; "> </td><td style="max-width:65%; width:750.641px; min-width:65%;;text-align: left ;  vertical-align: middle; "> </td></tr><tr><td style="max-width:10%; width:115.469px; min-width:10%;;text-align: left ;  vertical-align: middle; ">Contact:</td><td style="max-width:25%; width:288.703px; min-width:25%;;text-align: left ;  vertical-align: middle; "><strong>Trinity Biotech plc</strong></td><td style="max-width:65%; width:750.641px; min-width:65%;;text-align: left ;  vertical-align: middle; "><strong>RedChip Companies Inc.</strong></td></tr><tr><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; ">Paul Murphy</td><td style="text-align: left ;  vertical-align: middle; ">Dave Gentry, CEO</td></tr><tr><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; ">(353)-1-2769800</td><td style="text-align: left ;  vertical-align: middle; ">(1)-407-644-4256</td></tr><tr><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; ">(1)-800-RED-CHIP (733-2447)</td></tr><tr><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; "> </td><td style="text-align: left ;  vertical-align: middle; "><a href="mailto:TRIB@redchip.com" rel="nofollow" target="_blank">TRIB@redchip.com</a></td></tr></table> <p align="justify" style="text-align: justify;"><br></br></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1NDI3NiM3NjgzMTg2IzIwMTg5MTU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MGUwYzgxOTQtYTAyZC00ZjBlLTk1MWItODZiYWUyODZiYmZmLTEwMzA0ODgtMjAyNi0wNi0yOS1lbg==/tiny/Trinity-Biotech-plc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/23a9d0e4-6c22-4509-971e-0c09c45ec985"><img src="https://ml.globenewswire.com/media/23a9d0e4-6c22-4509-971e-0c09c45ec985/small/trinity-biotech-plc-logo.jpg" border="0" width="150" height="32" alt="Primary Logo"></img></a></p>

Trinity Biotech plc announced it has formally terminated its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global, and will not use the SEPA going forward. The move suggests a shift in financing strategy and could reduce near-term dilution risk, while the company emphasizes cash position and growth from Waveform assets and acquisitions. Investors should monitor liquidity runway and Waveform-related opportunities.

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News